Scholarlink

Background <p>Diabetes mellitus is still a major global health concern, and current treatments mostly target glycemic control rather than the underlying loss of β-cells that produce insulin. Type 2 diabetes is characterized by insulin resistance and β-cell depletion, whereas type 1 diabetes is caused by autoimmune-mediated β-cell death. Exogenous insulin, oral medications, and lifestyle changes are examples of conventional treatments that reduce hyperglycemia without restoring endogenous β-cell function. Although stem cell-based treatments and islet transplantation have promise, their use is constrained by safety issues, immunological rejection, and donor availability. In this regard, CRISPR-Cas9 gene-editing technology has become a revolutionary instrument that can precisely reprogramme, regenerate, and shield βcells.</p> Main body <p>Main Body CRISPR-Cas9 enables targeted genetic alterations that promote β-cell growth, reprogram pancreatic cells into insulin-secreting cells, and shield regenerated β-cells from immune attack According to preclinical research, α-cells can be transformed into β-like cells and βcell replication can be accelerated by interfering with negative cell cycle regulators. In autoimmune conditions, immune-evasive tactics like upregulating protective molecules may guarantee the long-term survival of regenerated cells. Insulin production has been restored with controllable safety profiles thanks to early therapeutic uses, such as ex vivo alteration of patient-derived progenitors. CRISPR addresses the underlying cause of diabetes by facilitating long-lasting β-cell regeneration, setting it apart from traditional medications and transplantation. Off-target editing, immunological reactions to Cas proteins, transport obstacles, exorbitant expenses, and ethical issues are still problems. But developments in AIguided design, high-fidelity nucleases, and nanoparticle delivery are gradually improving safety and effectiveness, advancing CRISPR-based treatments into clinical application.</p> Conclusion <p>The management of diabetes has met an emerging early translational promise changing the horizons of treatment from symptomatic treatment to disease modification thanks to CRISPR-Cas9-mediated β-cell regeneration. Early evidence points to the possibility of therapeutic therapies that restore endogenous insulin production and lessen treatment dependence for the remainder of one’s life, despite the fact that there are still many obstacles to overcome. Transforming this promising technology into a broadly accessible treatment will require sustained innovation, thorough safety assessment, and fair access measures.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

CRISPR–CAS9 mediated beta-cell regeneration: a transformative step in diabetes management

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月22日

查看全文
  • Syeda Fadak Zahra Hujjat,
  • Syeda Hasnat Zahra

摘要

Background

Diabetes mellitus is still a major global health concern, and current treatments mostly target glycemic control rather than the underlying loss of β-cells that produce insulin. Type 2 diabetes is characterized by insulin resistance and β-cell depletion, whereas type 1 diabetes is caused by autoimmune-mediated β-cell death. Exogenous insulin, oral medications, and lifestyle changes are examples of conventional treatments that reduce hyperglycemia without restoring endogenous β-cell function. Although stem cell-based treatments and islet transplantation have promise, their use is constrained by safety issues, immunological rejection, and donor availability. In this regard, CRISPR-Cas9 gene-editing technology has become a revolutionary instrument that can precisely reprogramme, regenerate, and shield βcells.

Main body

Main Body CRISPR-Cas9 enables targeted genetic alterations that promote β-cell growth, reprogram pancreatic cells into insulin-secreting cells, and shield regenerated β-cells from immune attack According to preclinical research, α-cells can be transformed into β-like cells and βcell replication can be accelerated by interfering with negative cell cycle regulators. In autoimmune conditions, immune-evasive tactics like upregulating protective molecules may guarantee the long-term survival of regenerated cells. Insulin production has been restored with controllable safety profiles thanks to early therapeutic uses, such as ex vivo alteration of patient-derived progenitors. CRISPR addresses the underlying cause of diabetes by facilitating long-lasting β-cell regeneration, setting it apart from traditional medications and transplantation. Off-target editing, immunological reactions to Cas proteins, transport obstacles, exorbitant expenses, and ethical issues are still problems. But developments in AIguided design, high-fidelity nucleases, and nanoparticle delivery are gradually improving safety and effectiveness, advancing CRISPR-based treatments into clinical application.

Conclusion

The management of diabetes has met an emerging early translational promise changing the horizons of treatment from symptomatic treatment to disease modification thanks to CRISPR-Cas9-mediated β-cell regeneration. Early evidence points to the possibility of therapeutic therapies that restore endogenous insulin production and lessen treatment dependence for the remainder of one’s life, despite the fact that there are still many obstacles to overcome. Transforming this promising technology into a broadly accessible treatment will require sustained innovation, thorough safety assessment, and fair access measures.